Search - tctmd.com

Displaying 141 - 160 of 199

Sort: Relevancy | Date

News Conference News TCT 2018

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

L.A. McKeown

September 27, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Two: COAPT Prompts Round of Applause, Plus New Valve Insights

Shelley Wood

September 23, 2018

News Conference News TCT 2018

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

Yael L. Maxwell

September 23, 2018

News Daily News

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Michael O'Riordan

September 20, 2018

News Industry News

Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

September 18, 2018

News Conference News ESC 2018

TAVR Debris Captured by Sentinel Embolic Protection Differs by Valve Type

Yael L. Maxwell

September 06, 2018

Presentation The Structural Heart Disease Summit 2018

Evolut R Low-Risk

Presenter: Jeffrey J. Popma

June 21, 2018

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Conference News CRT 2018

Transcatheter Fix for Native Aortic Valve Regurgitation ‘Not Optimal’ but Getting Better

Shelley Wood

March 05, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Daily News

Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed

Michael O'Riordan

January 10, 2018

News Daily News

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Shelley Wood

January 05, 2018

Presentation TCT 2017

The Evolut R Low-risk Trial

Presenter: Jeffrey J. Popma

October 30, 2017

News Daily News

Severe Aortic Stenosis Gets Its Own Appropriate Use Criteria

Caitlin E. Cox

October 18, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Shelley Wood

September 27, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

Shelley Wood

July 31, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Advertisement

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

TCT 2018, Day Two: COAPT Prompts Round of Applause, Plus New Valve Insights

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

TAVR Debris Captured by Sentinel Embolic Protection Differs by Valve Type

Evolut R Low-Risk

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Transcatheter Fix for Native Aortic Valve Regurgitation ‘Not Optimal’ but Getting Better

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

The Evolut R Low-risk Trial

Severe Aortic Stenosis Gets Its Own Appropriate Use Criteria

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

TCTMD’s Top 10 Most Popular Stories for July 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content